Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Three of a (Peptic) Kind!

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The Reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Prognostic Impact of Mild Hypokalemia in Terms of Death and Stroke in the General Population-A Prospective Population Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association between antecedent blood pressure, hypertension-mediated organ damage and cardiovascular outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Does Estimated Pulse Wave Velocity Add Prognostic Information? MORGAM Prospective Cohort Project

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Morten Rix Hansen
  • Asbjørn Hróbjartsson
  • Lars Videbæk
  • Zandra Nymand Ennis
  • Manan Pareek
  • Niels Herluf Paulsen
  • Martin Broe
  • Morten Olesen
  • Anton Pottegård
  • Per Damkier
  • Jesper Hallas
Vis graf over relationer

Background: Outcome postponement has been proposed as an effect measure for preventive drug treatment. It describes the average delay of the investigated unwanted clinical event, achieved by taking medication. The objective was to estimate postponement of death for the following heart failure medications compared to placebo: beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), ARB added to ACE inhibitors, aldosterone antagonists, ivabradine, and renin antagonists. Methods: We searched Medline and Embase from inception of databases until October 2017. Eligibility criteria were randomized placebo-controlled heart failure trials, including at least 1000 participants, with survival as a prespecified outcome and a minimum trial duration of 1 year. We calculated the outcome postponement by modeling the area between survival curves. This area was modeled on the basis of the hazard ratio or relative risk, the rate of mortality in the placebo group, and the trial duration. All results were standardized to a 3-year trial duration to ensure comparability between treatments. Results: We identified 14 eligible trials, with a total of 52,014 patients. The results in terms of postponement of all-cause mortality was: beta-blockers 43.7 days (95% confidence interval [95% CI], 20.8-66.5), ACE inhibitors 41.0 days (95% CI, 18.8-63.3), and aldosterone-antagonists 41.3 days (95% CI, 14.3,68.4). Conclusion: The modeled outcome postponement estimates reiterate beta-blockers, ACE inhibitors, and aldosterone antagonists as the mainstay of heart failure treatment. Furthermore, ivabradine or ARBs added to ACE inhibitors results in no statistically significant gain in survival.

OriginalsprogEngelsk
TidsskriftAmerican Journal of Medicine
Vol/bind133
Udgave nummer6
Sider (fra-til)e280-e289
ISSN0002-9343
DOI
StatusUdgivet - jun. 2020

Bibliografisk note

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

ID: 59580085